Denali Therapeutics Inc.
DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also developsā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$21.43
Price+0.56%
$0.12
1Y
Price
Market Cap
$3.346b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR+34.9%
3y CAGR+56.9%
5y CAGREarnings
-$512.540m
-21.2%
1y CAGR-52.3%
3y CAGR-42.3%
5y CAGREPS
-$2.97
-15.6%
1y CAGR-32.9%
3y CAGR-26.9%
5y CAGRBook Value
$1.014b
$1.145b
Assets$131.093m
Liabilities$42.288m
DebtDebt to Assets
3.7%
-0.1x
Debt to EBITDAFree Cash Flow
-$422.102m
-16.1%
1y CAGR-18.5%
3y CAGR-18.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company